Are dip tests needed for onabotulinumtoxinA (onabotA [Botox]) bladder procedures when no symptoms of urinary tract infection are present? A recent study presented at the AUA annual meeting in Chicago suggests the answer may be no.
A panel of experts discuss recent updates on the use of MRI/ultrasound fusion-guided biopsy in patients with prostate cancer.
“There is no clear evidence that adding metformin to standard of care increases overall survival in unselected patients with metastatic hormone-sensitive disease,” said Silke Gillessen,…
Andrea Necchi, MD, reported that pCR was 42% (95% CI, 28-56) in cohort 1 and 23% (95% CI, 10-41) in cohort 2.
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
At a median follow-up of 9 months, the confirmed objective response rate to disitamab vedotin plus pembrolizumab was 75% in the overall population.
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
“We already have very effective ARPIs available around the world, and this will add to those therapeutic options to try to tailor patients based on…
In the experimental arm, 41% of patients had an undetectable PSA level at week 48 vs 16% in the control arm (OR=3.88; 95% CI, 1.61-9.38,…
“What we’ve shown is [EV/pembrolizumab] outperforming chemotherapy in all subgroups,” says Thomas B. Powles, MBBS, MRCP, MD.
